Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

FormBlends vs Ondra Health

Two GLP-1 desks, one scoreboard. We put FormBlends and Ondra Health head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 377 · Grade C

FormBlends

Visit FormBlends Full brief →
vs
Higher Brief ScoreNo. 14 · Grade B+

Ondra Health

Visit Ondra Health Full brief →

The verdict

Ondra Health takes this head-to-head.

Ondra Health scores 87 to 57 on our six-factor Brief Score — A rare combination of a rock-bottom $93 semaglutide, brand-name access, LegitScript certification and all-50-state reach.

That doesn't make FormBlends a bad call — it's best for shoppers wanting a low compounded-semaglutide entry price with lots of on-site education. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
48
88
Supply Reliability
75
86
Transparency
32
88
Access Breadth
56
90
Clinical Oversight
76
88
Track Record
65
82
FormBlendsBrief Score 57 · 87Ondra Health

Price, coverage & the tracker

FormBlendsOndra Health
Brief Score57/100 (C)87/100 (B+)
SemaglutideFrom $99/mo (compounded)$93/mo
TirzepatideFrom $349/mo (compounded)$166/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerNewnew to the tracker, no prior readingStableprice stable

FormBlends: New to the tracker on 1 August 2026. The published line reads From $99/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Ondra Health: $93 sema / $166 tirz — the lowest accredited nationwide line we track; brand access + LegitScript.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.